



Press Release

Wednesday, December, 1, 2010



Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531

NSE: STAR

**STRIDES ARCOLAB ANNOUNCES US FDA APPROVAL OF
MIDAZOLAM HYDROCHLORIDE INJECTION**

- **15th STERILE INJECTABLES APPROVAL IN 2010**

Strides Arcolab Limited (Strides) today announced that the U.S. Food and Drug Administration has granted approval of Midazolam Hydrochloride injection (preservative-free) 1 mg/mL (2, 5mL) and 5mg/mL (1, 2 mL) single dose vials.

Midazolam, a general anaesthetic, will be offered as a sterile, non-pyrogenic parenteral dosage form for intravenous or intramuscular injection. According to IMS data, the total market for Midazolam in the USA in 2009 approximated US\$ 51 million. The market size for the approved strengths of 1 mg/mL (2, 5mL) and 5mg/mL (1, 2 mL) single dose vials which is to be launched in the near future is US\$ 31 million. The market size for additional strengths of the multi dose vials, the approval for which is expected shortly, is US\$ 18 million.



Midazolam will be launched under the partnership between Strides and Sagent Pharmaceuticals wherein Strides is developing and supplying more than 25 injectable products for the USA market which will be marketed by Sagent.

About Midazolam Hydrochloride Injection

Midazolam is indicated for preoperative use (sedation, anxiolysis, amnesia), prior to or during diagnostic, therapeutic or endoscopic procedures, intravenously for induction of general anesthesia, and for continuous intravenous infusion for sedation of intubated and mechanically ventilated patients.

About Strides Arcolab Limited:

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.



The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.

To learn more about Sagent, please visit www.SagentPharma.com.

For further information, please contact:

Mr. V S Iyer Executive Director Ph: +91 80 6658 0111	Mr. Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 98803 76648 Email: maheshn@corvoshandwick.co.in
Mr. Kannan N (Investor Relations) Tel : +91 98450 54745	Ms. Kasturi Wasmatar, Corporate Voice/ Weber Shandwick Mobile: 99167 28393 Email: kasturi@corvoshandwick.co.in
Ms. Melissa Arulappan (Media) Tel: +91 98450 22389	

